Repeatability of hypoxia PET imaging using [18F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial

详细信息    查看全文

• 作者：Catharina M. L. Zegers ; Wouter van Elmpt&#8230
• 关键词：PET imaging ; HX4 ; Hypoxia ; Head and neck cancer ; Lung cancer
• 刊名：European Journal of Nuclear Medicine and Molecular Imaging
• 出版年：2015
• 出版时间：November 2015
• 年：2015
• 卷：42
• 期：12
• 页码：1840-1849
• 全文大小：1,991 KB
• 参考文献：1.Dubois LJ, Lieuwes NG, Janssen MH, Peeters WJ, Windhorst AD, Walsh JC, et al. Preclinical evaluation and validation of [18F]HX4, a promising hypoxia marker for PET imaging. Proc Natl Acad Sci U S A. 2011;108(35):14620鈥?. doi:10.鈥?073/鈥媝nas.鈥?102526108 .
  2.Chen L, Zhang Z, Kolb HC, Walsh JC, Zhang J, Guan Y. 18F-HX4 hypoxia imaging with PET/CT in head and neck cancer: a comparison with 18F-FMISO. Nucl Med Commun. 2012;33(10):1096鈥?02. doi:10.鈥?097/鈥婱NM.鈥?b013e3283571016鈥?/span> .CrossRef PubMed
  3.Wouters BG, van den Beucken T, Magagnin MG, Lambin P, Koumenis C. Targeting hypoxia tolerance in cancer. Drug Resist Updat. 2004;7(1):25鈥?0. doi:10.鈥?016/鈥媕.鈥媎rup.鈥?003.鈥?2.鈥?04 .CrossRef PubMed
  4.Walsh JC, Lebedev A, Aten E, Madsen K, Marciano L, Kolb HC. The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. Antioxid Redox Signal. 2014;21(10):1516鈥?4. doi:10.鈥?089/鈥媋rs.鈥?013.鈥?378 .PubMed Central CrossRef PubMed
  5.Wouters BG, Koritzinsky M, Chiu RK, Theys J, Buijsen J, Lambin P. Modulation of cell death in the tumor microenvironment. Semin Radiat Oncol. 2003;13(1):31鈥?1. doi:10.鈥?053/鈥媠rao.鈥?003.鈥?0004 .
  6.Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol. 2000;57(1):39鈥?3.CrossRef PubMed
  7.Thorwarth D, Eschmann SM, Paulsen F, Alber M. Hypoxia dose painting by numbers: a planning study. Int J Radiat Oncol Biol Phys. 2007;68(1):291鈥?00. doi:10.鈥?016/鈥媕.鈥媔jrobp.鈥?006.鈥?1.鈥?61 .CrossRef PubMed
  8.Sun JD, Liu Q, Wang J, Ahluwalia D, Ferraro D, Wang Y, et al. Selective tumor hypoxia targeting by hypoxia-activated prodrug TH-302 inhibits tumor growth in preclinical models of cancer. Clin Cancer Res. 2012;18(3):758鈥?0. doi:10.鈥?158/鈥?078-0432.鈥婥CR-11-1980 .CrossRef PubMed
  9.Wilson WR, Hay MP. Targeting hypoxia in cancer therapy. Nat Rev Cancer. 2011;11(6):393鈥?10. doi:10.鈥?038/鈥媙rc3064 .CrossRef PubMed
  10.Rami M, Dubois L, Parvathaneni NK, Alterio V, van Kuijk SJ, Monti SM, et al. Hypoxia-targeting carbonic anhydrase IX inhibitors by a new series of nitroimidazole-sulfonamides/sulfamides/sulfamates. J Med Chem. 2013;56(21):8512鈥?0. doi:10.鈥?021/鈥媕m4009532 .CrossRef PubMed
  11.Dubois L, Peeters SG, van Kuijk SJ, Yaromina A, Lieuwes NG, Saraya R, et al. Targeting carbonic anhydrase IX by nitroimidazole based sulfamides enhances the therapeutic effect of tumor irradiation: a new concept of dual targeting drugs. Radiother Oncol. 2013;108(3):523鈥?. doi:10.鈥?016/鈥媕.鈥媟adonc.鈥?013.鈥?6.鈥?18 .
  12.Thorwarth D, Alber M. Implementation of hypoxia imaging into treatment planning and delivery. Radiother Oncol. 2010;97(2):172鈥?. doi:10.鈥?016/鈥媕.鈥媟adonc.鈥?010.鈥?5.鈥?12 .CrossRef PubMed
  13.Lambin P, van Stiphout RG, Starmans MH, Rios-Velazquez E, Nalbantov G, Aerts HJ, et al. Predicting outcomes in radiation oncology 鈥?multifactorial decision support systems. Nat Rev Clin Oncol. 2013;10(1):27鈥?0. doi:10.鈥?038/鈥媙rclinonc.鈥?012.鈥?96 .PubMed Central CrossRef PubMed
  14.van Loon J, Janssen MH, Ollers M, Aerts HJ, Dubois L, Hochstenbag M, et al. PET imaging of hypoxia using [18F]HX4: a phase I trial. Eur J Nucl Med Mol Imaging. 2010;37(9):1663鈥?. doi:10.鈥?007/鈥媠00259-010-1437-x .CrossRef PubMed
  15.Doss M, Zhang JJ, Belanger MJ, Stubbs JB, Hostetler ED, Alpaugh K, et al. Biodistribution and radiation dosimetry of the hypoxia marker 18F-HX4 in monkeys and humans determined by using whole-body PET/CT. Nucl Med Commun. 2010;31(12):1016鈥?4. doi:10.鈥?097/鈥婱NM.鈥?b013e3283407950鈥?/span> .PubMed Central PubMed
  16.Zegers CM, van Elmpt W, Wierts R, Reymen B, Sharifi H, Ollers MC, et al. Hypoxia imaging with [(18)F]HX4 PET in NSCLC patients: defining optimal imaging parameters. Radiother Oncol. 2013;109(1):58鈥?4. doi:10.鈥?016/鈥媕.鈥媟adonc.鈥?013.鈥?8.鈥?31 .CrossRef PubMed
  17.Zips D, Zophel K, Abolmaali N, Perrin R, Abramyuk A, Haase R, et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol. 2012;105(1):21鈥?. doi:10.鈥?016/鈥媕.鈥媟adonc.鈥?012.鈥?8.鈥?19 .CrossRef PubMed
  18.Okamoto S, Shiga T, Yasuda K, Ito YM, Magota K, Kasai K, et al. High reproducibility of tumor hypoxia evaluated by 18F-fluoromisonidazole PET for head and neck cancer. J Nucl Med. 2013;54(2):201鈥?. doi:10.鈥?967/鈥媕numed.鈥?12.鈥?09330 .
  19.Nehmeh SA, Lee NY, Schroder H, Squire O, Zanzonico PB, Erdi YE, et al. Reproducibility of intratumor distribution of (18)F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):235鈥?2. doi:10.鈥?016/鈥媕.鈥媔jrobp.鈥?007.鈥?8.鈥?36 .
  20.Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV, et al. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging. 2013;40(2):186鈥?7. doi:10.鈥?007/鈥媠00259-012-2258-x .
  21.de Langen AJ, Vincent A, Velasquez LM, van Tinteren H, Boellaard R, Shankar LK, et al. Repeatability of 18F-FDG uptake measurements in tumors: a metaanalysis. J Nucl Med. 2012;53(5):701鈥?. doi:10.鈥?967/鈥媕numed.鈥?11.鈥?95299 .
  22.Peeters SG, Zegers CM, Yaromina A, van Elmpt W, Dubois L, Lambin P. Current preclinical and clinical applications of hypoxia PET imaging using 2-nitroimidazoles. Q J Nucl Med Mol Imaging. 2015;59(1):39鈥?7.
  23.Peeters SG, Zegers CM, Lieuwes NG, van Elmpt W, Eriksson J, van Dongen GA, et al. A comparative study of the hypoxia PET tracers [18F]HX4, [18F]FAZA, and [18F]FMISO in a preclinical tumor model. Int J Radiat Oncol Biol Phys. 2015;91(2):351鈥?. doi:10.鈥?016/鈥媕.鈥媔jrobp.鈥?014.鈥?9.鈥?45 .
  24.Bittner MI, Wiedenmann N, Bucher S, Hentschel M, Mix M, Weber WA, et al. Exploratory geographical analysis of hypoxic subvolumes using 18F-MISO-PET imaging in patients with head and neck cancer in the course of primary chemoradiotherapy. Radiother Oncol. 2013;108(3):511鈥?. doi:10.鈥?016/鈥媕.鈥媟adonc.鈥?013.鈥?6.鈥?12 .
  25.Mortensen LS, Johansen J, Kallehauge J, Primdahl H, Busk M, Lassen P, et al. FAZA PET/CT hypoxia imaging in patients with squamous cell carcinoma of the head and neck treated with radiotherapy: results from the DAHANCA 24 trial. Radiother Oncol. 2012;105(1):14鈥?0. doi:10.鈥?016/鈥媕.鈥媟adonc.鈥?012.鈥?9.鈥?15 .
  26.Servagi-Vernat S, Differding S, Hanin FX, Labar D, Bol A, Lee JA, et al. A prospective clinical study of 18F-FAZA PET-CT hypoxia imaging in head and neck squamous cell carcinoma before and during radiation therapy. Eur J Nucl Med Mol Imaging. 2014;41(8):1544鈥?2. doi:10.鈥?007/鈥媠00259-014-2730-x .
  27.Zegers CM, van Elmpt W, Reymen B, Even AJ, Troost EG, Ollers MC, et al. In vivo quantification of hypoxic and metabolic status of NSCLC tumors using [18F]HX4 and [18F]FDG-PET/CT imaging. Clin Cancer Res. 2014;20(24):6389鈥?7. doi:10.鈥?158/鈥?078-0432.鈥婥CR-14-1524 .CrossRef PubMed
  28.Petit SF, Dekker AL, Seigneuric R, Murrer L, van Riel NA, Nordsmark M, et al. Intra-voxel heterogeneity influences the dose prescription for dose-painting with radiotherapy: a modelling study. Phys Med Biol. 2009;54(7):2179鈥?6. doi:10.鈥?088/鈥?031-9155/鈥?4/鈥?/鈥?22 .CrossRef PubMed
  29.Clausen MM, Hansen AE, Af Rosenschold PM, Kjaer A, Kristensen AT, McEvoy FJ, et al. Dose escalation to high-risk sub-volumes based on non-invasive imaging of hypoxia and glycolytic activity in canine solid tumors: a feasibility study. Radiat Oncol. 2013;8:262. doi:10.鈥?186/鈥?748-717X-8-262 .PubMed Central CrossRef PubMed
  30.Boellaard R. Standards for PET image acquisition and quantitative data analysis. J Nucl Med. 2009;50 Suppl 1:11S鈥?0. doi:10.鈥?967/鈥媕numed.鈥?08.鈥?57182 .
  31.Verwer EE, van Velden FH, Bahce I, Yaqub M, Schuit RC, Windhorst AD, et al. Pharmacokinetic analysis of [18F]FAZA in non-small cell lung cancer patients. Eur J Nucl Med Mol Imaging. 2013;40(10):1523鈥?1. doi:10.鈥?007/鈥媠00259-013-2462-3 .CrossRef PubMed
  
• 作者单位：Catharina M. L. Zegers (1)
  Wouter van Elmpt (1)
  Katrin Szardenings (2)
  Hartmuth Kolb (3)
  Alan Waxman (4)
  Rathan M. Subramaniam (5) (9)
  Dae Hyuk Moon (6)
  Jacqueline C. Brunetti (7)
  Shyam M. Srinivas (8)
  Philippe Lambin (1)
  David Chien (3)
  
  1. Department of Radiation Oncology (MAASTRO), GROW - School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands
  2. Threshold Pharmaceuticals, 170 Harbor Way, South San Francisco, CA, 94080, USA
  3. Siemens Molecular Imaging Biomarker Research, Siemens Medical Solutions USA, Inc., 6100 Bristol Parkway, Culver City, CA, USA
  4. Cedars-Sinai Medical Center, Los Angeles, CA, USA
  5. Boston University School of Medicine, Boston, MA, USA
  9. Division of Nuclear Medicine, Russell H Morgan Department of Radiology and Radiologic Sciences, Johns Hopkins Medical Institutions, Baltimore, MD, USA
  6. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea
  7. Holy Name Medical Center, Teaneck, NJ, USA
  8. Department of Nuclear Medicine, Imaging Institute, Cleveland Clinic, Cleveland, OH, 44195, USA
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Nuclear Medicine
  Imaging and Radiology
  Orthopedics
  Cardiology
  Oncology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1619-7089

文摘

Purpose Hypoxia is an important factor influencing tumor progression and treatment efficacy. The aim of this study was to investigate the repeatability of hypoxia PET imaging with [18F]HX4 in patients with head and neck and lung cancer.